https://www.yiliao.com/index.php?action=history&feed=atom&title=Ociperlimab
Ociperlimab - 版本历史
2026-04-18T00:08:55Z
本wiki的该页面的版本历史
MediaWiki 1.35.1
https://www.yiliao.com/index.php?title=Ociperlimab&diff=313202&oldid=prev
223.160.138.166：建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面
2026-01-06T05:12:38Z
<p>建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面</p>
<p><b>新页面</b></p><div><div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff; max-width: 1200px; margin: auto;"><br />
<br />
<div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;"><br />
<p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;"><br />
<strong>[[欧司珀利单抗]]([[Ociperlimab]])</strong>，研发代码为<strong>[[BGB-A1217]]</strong>，是一种在研的、具有高度特异性和亲和力的全人源化<strong>[[IgG1]]</strong>型单克隆抗体，靶向免疫检查点<strong>[[TIGIT]]</strong>（具免疫球蛋白和[[ITIM]]结构域的T细胞免疫受体）。该药物由<strong>[[百济神州]]([[BeiGene]])</strong>自主研发。在2026年的肿瘤免疫版图中，[[Ociperlimab]]被视为继<strong>[[PD-1]]</strong>/<strong>[[PD-L1]]</strong>之后的“第二波”免疫检查点抑制剂代表，通过阻断[[TIGIT]]与配体<strong>[[PVR]]([[CD155]])</strong>的结合，解除对<strong>[[NK细胞]]</strong>及<strong>[[效应T细胞]]</strong>的抑制。临床研究重点聚焦于其与<strong>[[替雷利珠单抗]]</strong>联合，治疗<strong>[[非小细胞肺癌]]([[NSCLC]])</strong>、<strong>[[食管鳞癌]]([[ESCC]])</strong>等多种晚期实体瘤。<br />
</p><br />
</div><br />
<br />
<div class="medical-infobox mw-collapsible mw-collapsed" style="width: 100%; max-width: 320px; margin: 0 auto 35px auto; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;"><br />
<br />
<div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #e0f2fe 0%, #bae6fd 100%); text-align: center; cursor: pointer;"><br />
<div style="font-size: 1.2em; font-weight: bold; letter-spacing: 1.2px;">欧司珀利单抗</div><br />
<div style="font-size: 0.7em; opacity: 0.85; margin-top: 4px; white-space: nowrap;">Ociperlimab (BGB-A1217)·点击展开</div><br />
</div><br />
<br />
<div class="mw-collapsible-content"><br />
<div style="padding: 25px; text-align: center; background-color: #f8fafc;"><br />
<div style="display: inline-block; background: #ffffff; border: 1px solid #e2e8f0; border-radius: 12px; padding: 20px; box-shadow: 0 4px 10px rgba(0,0,0,0.04);"><br />
<div style="width: 140px; height: 90px; background-color: #f1f5f9; display: flex; align-items: center; justify-content: center; color: #94a3b8; font-size: 0.8em; padding: 10px; text-align: center;">TIGIT/Ociperlimab Binding Complex</div><br />
</div><br />
<div style="font-size: 0.8em; color: #64748b; margin-top: 12px; font-weight: 600;">核心靶点：[[TIGIT]]</div><br />
</div><br />
<br />
<table style="width: 100%; border-spacing: 0; border-collapse: collapse; font-size: 0.85em;"><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0; width: 40%;">[[Entrez]]ID</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">201633</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">[[HGNC]]编号</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">30861</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">[[UniProt]]</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">Q495A1</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">药物类型</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">全人源化IgG1单抗</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">分子量</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">约146kDa</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">主要药企</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #1e40af;">[[百济神州]]</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569;">2026状态</th><br />
<td style="padding: 12px; color: #1e40af;">多项III期临床推进中</td><br />
</tr><br />
</table><br />
</div><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">分子机制：多重免疫激活路径</h2><br />
<br />
<p style="margin: 15px 0; text-align: justify;"><br />
[[Ociperlimab]]通过精准打击肿瘤微环境(<strong>[[TME]]</strong>)中的抑制性信号轴发挥作用：<br />
</p><br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>竞争性阻断配体结合：</strong><br />
[[TIGIT]]与活化受体<strong>[[CD226]]</strong>竞争性结合相同的配体<strong>[[PVR]]([[CD155]])</strong>。[[Ociperlimab]]阻断[[TIGIT]]后，使[[PVR]]更多地结合[[CD226]]，从而增强免疫细胞的共刺激信号。</li><br />
<li style="margin-bottom: 12px;"><strong>Fc 段介导的效应功能：</strong><br />
与部分竞争产品的[[IgG4]]设计不同，[[Ociperlimab]]采用有活性的<strong>[[IgG1]]</strong>骨架。2026年的分子机制研究确认，这能通过<strong>[[ADCC]]</strong>效应选择性减少肿瘤浸润的抑制性<strong>[[调节性T细胞]]([[Tregs]])</strong>。</li><br />
<li style="margin-bottom: 12px;"><strong>与PD-1的协同效应：</strong><br />
[[PD-1]]和[[TIGIT]]在耗竭型T细胞上共表达。[[Ociperlimab]]联合[[替雷利珠单抗]]可实现对免疫刹车系统的“双重锁定”，在[[PD-L1]]高表达人群中展现出显著的增效空间。</li><br />
</ul><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">2026核心临床研究图谱([[AdvanTIG]]系列)</h2><br />
<br />
<div style="overflow-x: auto; margin: 30px auto; max-width: 95%;"><br />
<table style="width: 100%; border-collapse: collapse; border: 1.2px solid #cbd5e1; font-size: 0.92em; text-align: left;"><br />
<tr style="background-color: #f8fafc; border-bottom: 2px solid #0f172a;"><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #0f172a; width: 25%;">研究编号</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #475569;">适应症领域(2026)</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #1e40af;">临床价值/状态</th><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">[[AdvanTIG-302]]</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">[[PD-L1]]高表达的初治晚期[[NSCLC]]。</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;"><strong>关键III期</strong>。对比替雷利珠单抗单药，旨在提升[[PFS]]。</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">[[AdvanTIG-203]]</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">既往接受过免疫治疗失败的[[ESCC]]。</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">探索免疫耐药后的<strong>挽救治疗</strong>潜力。</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">[[AdvanTIG-202]]</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">晚期复发性[[宫颈癌]]。</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">二期数据展示了优异的持久缓解率。</td><br />
</tr><br />
</table><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">2026治疗策略：精准筛选与双靶向模式</h2><br />
<p style="margin: 15px 0; text-align: justify;"><br />
[[Ociperlimab]]在2026年的临床应用路径高度依赖生物标志物的精准引导：<br />
</p><br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>PVR 表达作为潜在指标：</strong> 2026版专家共识建议，肿瘤组织中<strong>[[CD155]]([[PVR]])</strong>的高表达可能是预测[[Ociperlimab]]应答的关键标志物。</li><br />
<li style="margin-bottom: 12px;"><strong>免疫不良反应管理：</strong> 联合用药并未显著增加[[PD-1]]单药之外的毒性。2026规范重点关注潜在的<strong>[[免疫相关性肺炎]]</strong>及皮疹的早期监测。</li><br />
<li style="margin-bottom: 12px;"><strong>去化疗方案探索：</strong> 在[[PD-L1]]强阳性(TPS≥50%)的肺癌患者中，[[Ociperlimab]]联合[[替雷利珠单抗]]正挑战传统的“含铂化疗+免疫”模式。</li><br />
</ul><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">关键相关概念</h2><br />
<div style="background-color: #f8fafc; border: 1px solid #e2e8f0; border-radius: 8px; padding: 15px; margin: 20px 0;"><br />
<ul style="margin: 0; padding-left: 20px; color: #334155;"><br />
<li style="margin-bottom: 8px;"><strong>[[TIGIT]]：</strong> 2026年最具转化前景的抑制性免疫受体之一。</li><br />
<li style="margin-bottom: 8px;"><strong>[[替雷利珠单抗]]：</strong> [[Ociperlimab]]的“黄金搭档”，百济神州核心[[PD-1]]产品。</li><br />
<li style="margin-bottom: 8px;"><strong>[[CD226]]：</strong> TIGIT信号轴的正向调节对手，决定免疫激活的上限。</li><br />
<li style="margin-bottom: 8px;"><strong>[[Tiragolumab]]：</strong> 罗氏开发的同类竞品，其早期试验波动为[[Ociperlimab]]的设计提供了参考。</li><br />
</ul><br />
</div><br />
<br />
<div style="font-size: 0.92em; line-height: 1.6; color: #1e293b; margin-top: 50px; border-top: 2.2px solid #0f172a; padding: 15px 25px; background-color: #f8fafc; border-radius: 0 0 10px 10px;"><br />
<span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">学术参考文献与权威点评</span><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[1] <strong>Niu J,et al.(2022/2025Revision).</strong> <em>Ociperlimab,an anti-TIGIT antibody,combined with Tislelizumab in patients with advanced solid tumors.</em> <strong>[[The Journal of Clinical Oncology]]</strong>.<br><br />
<span style="color: #475569;">[权威点评]：该项Ib期研究数据确立了[[Ociperlimab]]双免疫方案在实体瘤中的安全性及初步抗肿瘤活性。</span><br />
</p><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[2] <strong>BeiGene R&D Pipeline Analysis(2025/2026).</strong> <em>Mechanistic advantages of IgG1-based TIGIT blockade in Ociperlimab development.</em> [Academic Review]<br><br />
<span style="color: #475569;">[学术点评]：2026年的综述强调了[[Ociperlimab]]通过[[ADCC]]活性清除[[Tregs]]，是其区别于同类[[IgG4]]药物的核心生物学护城河。</span><br />
</p><br />
</div><br />
<br />
<div style="margin: 40px 0; border: 1px solid #e2e8f0; border-radius: 8px; overflow: hidden; font-family: 'Helvetica Neue', Arial, sans-serif; font-size: 0.9em;"><br />
<div style="background-color: #eff6ff; color: #1e40af; padding: 8px 15px; font-weight: bold; text-align: center; border-bottom: 1px solid #dbeafe;"><br />
欧司珀利单抗 (Ociperlimab) · 知识图谱<br />
</div><br />
<table style="width: 100%; border-collapse: collapse; background-color: #ffffff;"><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">关联靶点</td><br />
<td style="padding: 10px 15px; color: #334155;">[[TIGIT]]•[[PD-1]]•[[CD155]]•[[CD226]]•[[LAG-3]]</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">治疗组合</td><br />
<td style="padding: 10px 15px; color: #334155;">[[替雷利珠单抗]]•[[含铂化疗]]•[[靶向药物]]</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">核心临床</td><br />
<td style="padding: 10px 15px; color: #334155;">[[AdvanTIG-302]]•[[AdvanTIG-301]]•[[AdvanTIG-204]]</td><br />
</tr><br />
<tr><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">竞争对手</td><br />
<td style="padding: 10px 15px; color: #334155;">[[Tiragolumab]]•[[Domvanalimab]]•[[Vibostolimab]]</td><br />
</tr><br />
</table><br />
</div><br />
<br />
</div></div>
223.160.138.166